Timothy Coughlin
CIK: 0001376043
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (15 total)
- Jun 12, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct10K shares at avg. $50.07$501K - Jun 12, 2026TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct10K shares at avg. $26.52$265K - Jun 9, 2026VIR
Vir Biotechnology, Inc.
Award(A)Direct8K shares- - Jun 9, 2026VIR
Vir Biotechnology, Inc.
Award(A)Direct8K shares- - Jun 3, 2026ADCT
ADC Therapeutics SA
Tax Payment(F)Direct12.6K shares at avg. $3.08$39K - Jun 1, 2026ADCT
ADC Therapeutics SA
Award(A)Direct45K shares- - May 19, 2026TVTX
Travere Therapeutics, Inc.
Award(A)Direct4K shares- - May 15, 2026TVTX
Travere Therapeutics, Inc.
Sale(S)Direct3.3K shares at avg. $43.49$141K - May 11, 2026ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares- - Oct 31, 2025TVTX
Travere Therapeutics, Inc.
Sale(S)Direct18K shares at avg. $35.03$631K - Oct 31, 2025TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct10K shares at avg. $17.44$174K - Oct 31, 2025TVTX
Travere Therapeutics, Inc.
Exercise(M)Direct8K shares at avg. $16.33$131K - Jun 3, 2025ADCT
ADC Therapeutics SA
Award(A)Direct40K shares- - May 15, 2025TVTX
Travere Therapeutics, Inc.
Award(A)Direct6.5K shares- - May 1, 2025ATYR
aTYR PHARMA INC
Award(A)DirectStock Option (right to buy)
50K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 12, 2026 |  TVTX Travere Therapeutics, Inc. | Sale(S) | 10,000 | $50.07 | $500,747 | Direct |
| Jun 12, 2026 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 10,000 | $26.52 | $265,200 | Direct |
| Jun 9, 2026 |  VIR Vir Biotechnology, Inc. | Award(A) | 8,000 | - | $0 | Direct |
| Jun 9, 2026 | VIR Vir Biotechnology, Inc. | Award(A) | 8,000 | - | $0 | Direct |
| Jun 3, 2026 |  ADCT ADC Therapeutics SA | Tax Payment(F) | 12,600 | $3.08 | $38,808 | Direct |
| Jun 1, 2026 | ADCT ADC Therapeutics SA | Award(A) | 45,000 | - | $0 | Direct |
| May 19, 2026 | TVTX Travere Therapeutics, Inc. | Award(A) | 4,000 | - | $0 | Direct |
| May 15, 2026 | TVTX Travere Therapeutics, Inc. | Sale(S) | 3,250 | $43.49 | $141,343 | Direct |
| May 11, 2026 |  ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
| Oct 31, 2025 | TVTX Travere Therapeutics, Inc. | Sale(S) | 18,000 | $35.03 | $630,601 | Direct |
| Oct 31, 2025 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 10,000 | $17.44 | $174,400 | Direct |
| Oct 31, 2025 | TVTX Travere Therapeutics, Inc. | Exercise(M) | 8,000 | $16.33 | $130,640 | Direct |
| Jun 3, 2025 | ADCT ADC Therapeutics SA | Award(A) | 40,000 | - | - | Direct |
| May 15, 2025 | TVTX Travere Therapeutics, Inc. | Award(A) | 6,500 | - | - | Direct |
| May 1, 2025 | ATYR aTYR PHARMA INC | Award(A) Stock Option (right to buy) | 50,000 | - | - | Direct |
1-15 of 15 transactions
About Coughlin Timothy
Coughlin Timothy (SEC CIK 0001376043) files insider reports with the SEC as Director of Travere Therapeutics, Inc. (TVTX), Director of Vir Biotechnology, Inc. (VIR) and Director of ADC Therapeutics SA (ADCT). Signal8 also holds filings tied to 1 other company.
Signal8 holds 12 ownership filings by Coughlin Timothy (2 Form 3, 10 Form 4), filed between May 2, 2025 and Jun 16, 2026. Those filings report 15 transactions, from May 1, 2025 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Coughlin Timothy's filings is in NEW PROVIDENCE, NJ.
Recent filings by Coughlin Timothy
- Jun 12, 2026: Open-market sale of TVTX shares (Form 4, code S).
- Jun 12, 2026: Option exercise of TVTX shares (Form 4, code M).
- Jun 9, 2026: Grants or awards of VIR shares (2 lines, Form 4, code A).
- Jun 3, 2026: Tax withholding of ADCT shares (Form 4, code F).
- Jun 1, 2026: Grant or award of ADCT shares (Form 4, code A).
Other insiders filing for Travere Therapeutics, Inc. (TVTX)
- Dube Eric M, CHIEF EXECUTIVE OFFICER
- ROTE WILLIAM E., Chief Research Officer
- Heerma Peter, EVP, CHIEF COMMERCIAL OFFICER
- Inrig Jula, EVP, Head of R&D & CMO
- REED ELIZABETH E, Chief Legal Officer and GC
- Cline Christopher R., CHIEF FINANCIAL OFFICER